The Choosing Wisely RI campaign promotes productive conversations between patients and doctor--conversations that research shows produce the right level of care and go a long way towards eliminating tests, procedures and medications that provide, little, if any benefit. The campaign is organized and promoted by the Rhode Island Business Group on Health (RIBGH) and draws on the expertise of the American Board of Internal Medicine Foundation. While we provide materials that enable patients to have informed conversations with their doctors and other health care providers, we do not provide any individual medical advice.
Choosing Wisely provides employees free-of-charge access to online tools developed by ABIMF and their 80+ Specialty Society partners.
The Choosing Wisely Mobile Phone App for Apple and Android phones gives employees the chance to view the Choosing Wisely materials and recommendations on their phones - possibly when they are in their physician's office!
Get daily updates from Choosing Wisely RI on our Facebook page!
Join the more than 40 organizations who have already adopted Choosing Wisely. Launching the campaign for Your Employees is Easy!
Five Things Physicians and Patients Should Question
From the American Society of Hematology and the American Society of Pediatric Hematology/Oncology
September is Childhood Cancer Awareness Month. In honor of this observance, we have included Choosing Wisely’s recommendations on five treatments physicians and patients should question, from the American Society of Hematology and the American Society of Pediatric Hematology/Oncology:
According to the American Society of Hematology and the American Society of Pediatric Hematology/Oncology, hemostatic testing adds cost and may introduce additional stress, either due to blood sampling or if a child has “abnormal” results.
The risk of spontaneous bleeding is low at platelet counts greater than 10,000/mcL. According to the American Society of Hematology and the American Society of Pediatric Hematology/Oncology, unnecessary transfusions put patients at risk for transfusion reactions, alloimmunization, blood borne infections, and refractoriness to future platelet transfusions.
Results of testing on children with venous access have not shown to either predict recurrence of venous thrombosis or inform the intensity or duration of anticoagulant therapy. Thrombophilia testing has substantial financial cost, and a positive result has the potential for misinterpretation of risk assessment, leading to undue psychological distress or impact on possible life insurance discrimination for affected patients.
Asymptomatic pediatric patients with iron deficiency anemia do not transfuse packed red blood cells (pRBC) in the absence of hemodynamic instability or active bleeding. Unnecessary pRBC transfusions put patients at risk for complications, such as transfusion reactions, blood borne infections, and volume overload.
According to the American Society of Hematology and the American Society of Pediatric Hematology/Oncology, there is insufficient evidence to support the routine use of granulocyte colony stimulating factor (G-CSF) as a prophylaxis strategy to improve health outcomes in pediatric patients. The use of G-CSF in this population should be guided by clinical evaluation.
Choosing Wisely Mailing List
Do you find this information helpful? The RIBGH periodically sends out Choosing Wisely information and updates. Click here to join the mailing list!